What is Nurix Therapeutics, Inc.'s G&A?

Nurix Therapeutics, Inc. (NRIX) reported G&A of $14.61M in Q4 2025.

How has Nurix Therapeutics, Inc.'s G&A changed year-over-year?

Nurix Therapeutics, Inc.'s G&A increased by 25.4% year-over-year, from $11.65M to $14.61M.

What is the long-term trend for Nurix Therapeutics, Inc.'s G&A?

Over 4 years (2021 to 2025), Nurix Therapeutics, Inc.'s G&A has grown at a 14.0% compound annual growth rate (CAGR), from $31.2M to $52.74M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Nurix Therapeutics, Inc. NRIX G&A

G&A at other companies

Kymera TherapeuticsKYMR

$20.36M+25.1%

Monte Rosa Therapeutics, Inc.GLUE

$10.18M+16.9%

Celldex TherapeuticsCLDX

$11.45M+5.8%

Septerna, Inc.SEPN

$10.29M+50.0%

Dyne Therapeutics, Inc.DYN

$24.39M+53.1%

Apogee Therapeutics, Inc.APGE

$21.95M+31.4%

Other financials

Income statement

See full

Revenue$6.3M-66.1%

Operating income-$92.5M-47.1%

Net income-$87.2M-54.7%

EPS (diluted)-$0.79-17.9%

Balance sheet

See full

Cash & equivalents$72.2M-6.1%

Total debt$58.7M+120%

Total equity$480.9M0.0%

Total assets$636.1M+3.4%

Cash flow

See full

Operating cash flow-$71.9M-17.7%

CapEx$1.0M-70.0%

Free cash flow-$73.0M-13.0%

Valuation

See full

Market cap$1.95B+40.1%

Enterprise value$1.94B+45.1%

P/S27.2×+2.5×

Profitability

See full

Operating margin-439.3%+35.3pp

Net margin-411.4%+52.7pp

FCF margin-378.7%+24.1pp

Returns & leverage

See full

Return on equity-61.4%-2.5pp

Debt / equity0.1×+0.1×

Current ratio6×-0.3×

Where this comes from

Reported directly by Nurix Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nurix Therapeutics, Inc.'s g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Nurix Therapeutics, Inc.'s G&A?: Nurix Therapeutics, Inc. (NRIX) reported G&A of $14.61M in Q4 2025.
How has Nurix Therapeutics, Inc.'s G&A changed year-over-year?: Nurix Therapeutics, Inc.'s G&A increased by 25.4% year-over-year, from $11.65M to $14.61M.
What is the long-term trend for Nurix Therapeutics, Inc.'s G&A?: Over 4 years (2021 to 2025), Nurix Therapeutics, Inc.'s G&A has grown at a 14.0% compound annual growth rate (CAGR), from $31.2M to $52.74M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.